WHO approves Ranbaxy’s AIDS drug
Ranbaxy Laboratories Ltd announced on Friday that the World Health Organisation (WHO), Geneva, has approved and included another of the company’s Anti Retrovirals (ARV) drug in its pre-qualification list.
The product, Abacavir 300 mg tablets, will be manufactured at Ranbaxy’s WHO Pre-Qualified manufacturing site at Paonta Sahib.
Abacavir is a nucleoside reverse transcriptase inhibitor and is widely used as part of first line Anti Retroviral treatment around the world.
Commenting on the inclusion, Mr Malvinder Mohan Singh, CEO and Managing Director, Ranbaxy, said, “We are pleased to have one more product on the WHO pre-qualification list. This is yet another significant step in our effort to offer high quality, affordable ARV medicines, for the benefit of the needy HIV patients in the developing and developed parts of the world. We remain committed to supporting the global fight against HIV/AIDS.”
With the inclusion of Abacavir 300 tablets, Ranbaxy now has 18 ARVs on the WHO pre-qualification list, including three USFDA approvals.
|
08-11-2008, 06:25 PM
Linear Mode
